Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXA709c
- Development stage
- Preclinical
- Lead developer
- TAXIS Pharmaceuticals
- Modality
- Small Molecules
01
Overview
TXA709c is an investigational small-molecule efflux pump inhibitor (EPI) being developed by TAXIS Pharmaceuticals. It is designed to target and inhibit bacterial efflux pumps, which act as cellular defense mechanisms by actively expelling antibiotics from bacterial cells. By blocking these pumps, TXA709c prevents the extrusion of co-administered antibacterial agents, thereby increasing their intracellular concentration and restoring or enhancing their efficacy against multidrug-resistant (MDR) pathogens. The program is currently in preclinical development, with a primary focus on treating Gram-negative multidrug-resistant infections, including Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP).
- Other names
- EPIs
02
Targets
BEP (Bacterial multidrug efflux pump)
Beyond the preview
Go deeper on TXA709c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXA709c.